Literature DB >> 32341137

Differentiation between athlete's heart and dilated cardiomyopathy in athletic individuals.

Lynne Martina Millar1, Zephryn Fanton1, Gherardo Finocchiaro1, Gabriel Sanchez-Fernandez1, Harshil Dhutia1, Aneil Malhotra1,2, Ahmed Merghani1, Michael Papadakis1, Elijah R Behr1, Nick Bunce1, David Oxborough3, Matthew Reed1, Jamie O'Driscoll4, Maria Teresa Tome Esteban1, Andrew D'Silva1, Gerry Carr-White5, Jessica Webb5,6, Rajan Sharma1, Sanjay Sharma7.   

Abstract

OBJECTIVE: Distinguishing early dilated cardiomyopathy (DCM) from physiological left ventricular (LV) dilatation with LV ejection fraction <55% in athletes (grey zone) is challenging. We evaluated the role of a cascade of investigations to differentiate these two entities.
METHODS: Thirty-five asymptomatic active males with DCM, 25 male athletes in the 'grey zone' and 24 male athletes with normal LV ejection fraction underwent N-terminal pro-brain natriuretic peptide (NT-proBNP) measurement, ECG and exercise echocardiography. Grey-zone athletes and patients with DCM underwent cardiovascular magnetic resonance (CMR) and Holter monitoring.
RESULTS: Larger LV cavity dimensions and lower LV ejection fraction were the only differences between grey-zone and control athletes. None of the grey-zone athletes had abnormal NT-proBNP, increased ectopic burden/complex arrhythmias or pathological late gadolinium enhancement on CMR. These features were also absent in 71%, 71% and 50% of patients with DCM, respectively. 95% of grey-zone athletes and 60% of patients with DCM had normal ECG. During exercise echocardiography, 96% grey-zone athletes increased LV ejection fraction by >11% from baseline to peak exercise compared with 23% of patients with DCM (p<0.0001). Peak LV ejection fraction was >63% in 92% grey-zone athletes compared with 17% patients with DCM (p<0.0001). Failure to increase LV ejection fraction >11% from baseline to peak exercise or achieve a peak LV ejection fraction >63% had sensitivity of 77% and 83%, respectively, and specificity of 96% and 92%, respectively, for predicting DCM.
CONCLUSION: Comprehensive assessment using a cascade of routine investigations revealed that exercise stress echocardiography has the greatest discriminatory value in differentiating between grey-zone athletes and asymptomatic patients with DCM. Our findings require validation in larger studies. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  idiopathic dilated cardiomyopathy

Mesh:

Substances:

Year:  2020        PMID: 32341137     DOI: 10.1136/heartjnl-2019-316147

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  8 in total

1.  2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play: A Report of the American College of Cardiology Solution Set Oversight Committee.

Authors:  Ty J Gluckman; Nicole M Bhave; Larry A Allen; Eugene H Chung; Erica S Spatz; Enrico Ammirati; Aaron L Baggish; Biykem Bozkurt; William K Cornwell; Kimberly G Harmon; Jonathan H Kim; Anuradha Lala; Benjamin D Levine; Matthew W Martinez; Oyere Onuma; Dermot Phelan; Valentina O Puntmann; Saurabh Rajpal; Pam R Taub; Amanda K Verma
Journal:  J Am Coll Cardiol       Date:  2022-03-16       Impact factor: 27.203

2.  A case report of profound atrioventricular block in an endurance athlete: how far do you go?

Authors:  Mark Abela; John Bonello; Mark Adrian Sammut
Journal:  Eur Heart J Case Rep       Date:  2022-05-02

3.  Diagnostic Yield of Cardiac Magnetic Resonance in Athletes with and without Features of the Athlete's Heart and Suspected Structural Heart Disease.

Authors:  Łukasz A Małek; Barbara Miłosz-Wieczorek; Magdalena Marczak
Journal:  Int J Environ Res Public Health       Date:  2022-04-15       Impact factor: 4.614

4.  Establishment of a Dedicated Inherited Cardiomyopathy Clinic: From Challenges to Improved Patients' Outcome.

Authors:  Emily Smith; Paul D Thompson; Carolyn Burke-Martindale; Adaya Weissler-Snir
Journal:  J Am Heart Assoc       Date:  2022-04-26       Impact factor: 6.106

Review 5.  Screening of Potential Cardiac Involvement in Competitive Athletes Recovering From COVID-19: An Expert Consensus Statement.

Authors:  Dermot Phelan; Jonathan H Kim; Michael D Elliott; Meagan M Wasfy; Paul Cremer; Amer M Johri; Michael S Emery; Partho P Sengupta; Sanjay Sharma; Matthew W Martinez; Andre La Gerche
Journal:  JACC Cardiovasc Imaging       Date:  2020-10-28

Review 6.  Coronavirus Disease 2019: Cardiac Complications and Considerations for Returning to Sports Participation.

Authors:  Daniel X Augustine; Tracey Keteepe-Arachi; Aneil Malhotra
Journal:  Eur Cardiol       Date:  2021-03-02

7.  Rationale and design of the PROspective ATHletic Heart (Pro@Heart) study: long-term assessment of the determinants of cardiac remodelling and its clinical consequences in endurance athletes.

Authors:  Ruben De Bosscher; Christophe Dausin; Kristel Janssens; Jan Bogaert; Adrian Elliott; Olivier Ghekiere; Caroline M Van De Heyning; Prashanthan Sanders; Jonathan Kalman; Diane Fatkin; Lieven Herbots; Rik Willems; Hein Heidbuchel; André La Gerche; Guido Claessen
Journal:  BMJ Open Sport Exerc Med       Date:  2022-03-18

Review 8.  Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments.

Authors:  Nicoletta Orphanou; Efstathios Papatheodorou; Aris Anastasakis
Journal:  Heart Fail Rev       Date:  2021-07-14       Impact factor: 4.654

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.